Items where authors include "Cortes, J."

Article

Lee, M., Larose, H. orcid.org/0000-0003-4678-6048, Gräbeldinger, M. et al. (20 more authors) (2024) The evolving value assessment of cancer therapies: Results from a modified Delphi study. Health Policy OPEN, 6. 100116. ISSN 2590-2296

Saini, K.S., Lanza, C., Romano, M. et al. (10 more authors) (2020) Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. British Journal of Cancer, 123. pp. 694-697. ISSN 0007-0920

Schmid, P., Zaiss, M., Harper-Wynne, C. et al. (29 more authors) (2019) Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncology, 5 (11). pp. 1556-1564. ISSN 2374-2445

Yardley, D.A., Brufsky, A., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (10 more authors) (2016) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015). TRIALS, 17. p. 63. ISSN 1745-6215

Yardley, D.A., Brufsky, A., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (10 more authors) (2015) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 16. 575. ISSN 1745-6215

Proceedings Paper

Goetz, M.P., Wander, S.A., Bachelot, T. et al. (17 more authors) (2024) Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. American Society of Clinical Oncology .

Lee, M., Abrams, K., Baird, A.M. et al. (17 more authors) (2023) EHTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies. In: Value in Health. ISPOR Europe 2023, 11-15 Nov 2023. , S380-S380.

Lee, M., Abrams, K., Baird, A.M. et al. (17 more authors) (2023) HTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies. In: Value in Health. ISPOR Europe 2023, 11-15 Nov 2023, Copenhagen, Denmark. Elsevier , s380-s380.

Lee, M., Baird, A.-M., Brown, S. et al. (17 more authors) (2023) The evolving value assessment of cancer therapies: Principles from the cancer community. In: Journal of Clinical Oncology. 2023 ASCO Annual Meeting I, 02-06 Jun 2023, Chicago, IL. American Society of Clinical Oncology , Alexandria, Virginia, USA .